CTLA-4/FasL fusion protein (KAHR Medical)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameCTLA-4/FasL fusion protein (KAHR Medical)

Drug Alias NameKAHR-102

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionCluster of differentiation 86 inhibitorsApoptosis-mediating surface antigen FAS stimulantsCluster of differentiation 80 inhibitors

TargetsCluster of differentiation 80Cluster of differentiation 86Apoptosis-mediating surface antigen FAS

Therapy Area/IndicationsLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesKahr Medical

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesKahr Medical

Active IndicationsN/A

Inactive IndicationsLymphoma

Other Information

ATC CodeN/A